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SPARC (Secreted Protein Acidic and Rich in Cysteine)
, is a matricellular glycoprotein that is produced by tumor and/or neighboring stroma. In human prostate cancer, SPARC immunoreactivity is highest in metastatic lesions but distinct contributions of tumoral and stromal SPARC to tumorigenesis and progression are unclear. To determine the role of SPARC in primary prostate tumorigenesis, we crossed SPARC-null (SP À/À ) with TRAMP (Transgenic Adenocarcinoma of Mouse Prostate) mice.
mice exhibited accelerated cancer development and progression. Compared to their TRAMP þ /SP À/À counterparts, TRAMP þ /SP þ / þ tumors had fewer proliferating cells, and decreased cyclins A and D1 with increased p21
Cip and p27 Kip . Similar effects on proliferation and cell-cycle regulators were observed in human prostate cancer cell lines, transiently transfected with pSPARC. TRAMP þ /SP À/À tumors exhibited decreased stromal collagen, enhanced matrix metalloproteinase activity and increased vascular endothelial growth factor, proinflammatory cytokines. To determine the contribution of stromal SPARC, we evaluated subcutaneous tumor growth of TRAMP cell lines in syngeneic SP þ / þ and SP
Introduction
Prostate cancer is a common cause of morbidity and mortality in men in the United States (Jemal et al., 2008) . Molecular alterations in the tumor as well as the surrounding stroma (Kelloff et al., 2006 , and references cited therein) result in a complex microenvironment where malignant epithelial cells interact with host cells within an extracellular matrix (ECM) scaffold. The summation of these interactions ultimately determines the biological characteristics of tumor initiation, progression and organ-specific metastasis (Pienta et al., 2008) . Secreted protein acidic and rich in cysteine (SPARC; BM40 or osteonectin) is a nonstructural glycoprotein component of the ECM that has been associated with tissue remodeling and implicated in tumorigenesis (Said et al., 2007b; Podhajcer et al., 2008 , and references cited therein). The role of SPARC in the tumor microenvironment appears to be dependent on tumor type and location as well as on whether the molecule is produced by the neoplasm or neighboring stroma. High expression of SPARC in malignant cells is associated with enhanced tumor growth and metastasis, and is correlated with poor survival for patients with melanoma, esophageal cancer, glioma, and head and neck cancers (Ledda et al., 1997; Schultz et al., 2002; Yamashita et al., 2003; Chin et al., 2005; Kato et al., 2005) . In contrast, stromal SPARC inhibits angiogenesis and limits tumor growth in ovarian cancer and glioblastoma (Said and Motamed, 2005; Chlenski et al., 2006 Chlenski et al., , 2007 Said et al., 2007a, b) . Although stromal SPARC was correlated with poor prognosis in pancreatic and small cell lung cancer (Podhajcer et al., 2008) , tumor cell SPARC expression was lost due to promoter hypermethylation in pancreatic (Sato et al., 2003) , non-small cell lung (Suzuki et al., 2005; Pan et al., 2008) , colon (Tai et al., 2005; Yang et al., 2007; Cheetham et al., 2008) , cervical (Sova et al., 2006; Kahn et al., 2008) , endometrial (Rodriguez-Jimenez et al., 2007) and ovarian cancers (Socha et al., 2009) . Stromal SPARC may promote immune/inflammatory cell recruitment in the juxtatumoral stroma (Sangaletti et al., 2003) , but may also exert an antiinflammatory role (Said et al., 2007b; Pan et al., 2008) . The complex roles of SPARC in different tumors may be attributed to the bioavailability of either the whole molecule or its cleavage products that may have antagonistic effects in a given microenvironment, as well as its cellular and subcellular distribution (Podhajcer et al., 2008) .
The role of SPARC in prostate cancer remains incompletely understood. As it was identified as a major bone-derived chemoattractant for prostate cancer cells in vitro (Jacob et al., 1999; De et al., 2003; Koblinski et al., 2005; Chen et al., 2007) , it has been assumed to be important in human prostate cancer bone metastasis. SPARC immunostaining in human prostate cancer tissues was lower in primary tumors relative to lymph node and osseous metastatic foci (Thomas et al., 2000) . Gene expression array data of clinical samples from prostate cancer patients corroborate (Dhanasekaran et al., 2001; Lapointe et al., 2004; Tomlins et al., 2007) this finding. In addition, low or absent SPARC expression has been reported in metastatic human prostate cancer cell lines DU145, PC3 and their more aggressive derivatives Wong et al., 2008) . Recently, an interaction between prostate cancer cells and bone has been proposed as a potential explanation for the tropic nature of metastasis of prostate cancer to bone (Chen et al., 2007) . A secreted isoform of ErbB3 (p45-sErbB3) has been identified as a mediator of this interaction in bone marrow supernatants from men with bone metastatic prostate cancer. In addition, p45-sErbB3 was highly expressed in metastatic prostate cancer cells in bone but not primary tumors and in vitro studies identified SPARC as a p45-sErbB3-responsive gene.
Most studies addressing the role of SPARC in cancer have relied on retrospective analysis of human tumors, analysis of human or murine cancer cells in vitro or in vivo implantation into immunocompromised or syngeneic SP À/À mice. A few studies evaluated the role of this protein in spontaneous tumorigenesis and progression. For example, SP À/À mice were shown to be resistant to UV irradiation-induced squamous cell carcinomas (Aycock et al., 2004) and APC Min/ þ -induced spontaneous intestinal adenomas, relative to SP þ / þ animals (Sansom et al., 2007) . The role of endogenous SPARC in spontaneous carcinogenesis and metastasis has been studied by comparing SP þ /À and SP À/À mice interbred with transgenic adenocarcinoma of mouse prostate (TRAMP) or murine mammary tumor viruspolyoma middle T (Wong et al., 2008) . In this study, mice lacking SPARC expression were compared to those heterozygous for SPARC in a mixed genetic background. However, definite conclusions regarding the effects of SPARC on fibrillar collagen maturity and assembly and on various cellular and noncellular stromal components could not be drawn robustly given the known influence of genetic background on tumor formation in SP À/À mice (Bradshaw et al., 1999; Brekken et al., 2003; Francki et al., 2003; Koukourakis et al., 2003; Sangaletti et al., 2003; Puolakkainen et al., 2004; Said et al., 2007b) .
Here, we analysed the role of SPARC in primary prostate carcinogenesis and progression, using the C57/B6 TRAMP autochthonous murine prostate cancer model (Pienta et al., 2008) . Furthermore, three cell lines derived from primary TRAMP tumors as well as human prostate cancer cell lines were used to evaluate the in vitro and in vivo effect of SPARC in prostate cancer. Together these experiments begin to document the relative contribution of tumor and host SPARC in prostate carcinogenesis and progression.
Results
Germline SPARC deletion enhances tumor formation and metastasis in TRAMP mice SP À/À mice have normal viability and fertility (Gilmour et al., 1998) . Breeding SP À/À with TRAMP mice had no obvious macroscopic or microscopic effects on normal prostate glandular and ductal morphology (Supplementary Figures 1A and B) . The absence of SPARC protein did not affect expression of SV40-large T antigen and the expression of both was confirmed in normal prostate and tumor (Supplementary Figures 1C and D) . We compared prostate lobes (ventral prostate (VP), lateral prostate (LP), dorsal prostate (DP) and anterior prostate (AP)) individually, as each lobe develops cancer at a different frequency (Kaplan-Lefko et al., 2003) in
We recorded tissue histology (normal, prostate intraepithelial neoplasia (PIN), well-differentiated adenocarcinoma (WD adeno), poorly differentiated adenocarcinoma (PD adeno), small cell carcinoma (SCC) and phyllodes like (PLL)), in animals killed at three time points: 18-20 (p20), 21-30 and 31-50 (X31) weeks of age, according to previously described criteria (Greenberg et al., 1995; Gingrich et al., 1996; Kaplan-Lefko et al., 2003) . As SCC and PLL are tumor histologies that occur late or in hormonal-independent prostate cancer in the TRAMP mice (Kaplan-Lefko et al., 2003) , we included them in one category designated 'others'. Differences in the prevalence of lesions were observed as a function of time and lobe. In general, changes in VP were similar to those in the AP, whereas those in the LP were similar to those in DP, with lesions in the dorsal and lateral lobes (equivalent to the peripheral zone of human prostate) developing earlier (Maitland, 2008) . Most of the significant differences observed between T þ /SP À/À and T þ /SP þ / þ mice in prostate pathology were in the first and third cohorts (Figure 1a) .
We next compared the overall tumor burden of the disease at each timepoint in
, using a scoring system defined in Materials and methods, between both genotypes (Figure 1b) . We found that in the first cohort the incidence and aggressiveness of prostate cancer was higher in T þ /SP À/À mice (P ¼ 0.005). This difference was less apparent in the second cohort (P ¼ 0.059), whereas in the third cohort, T þ /SP À/À mice had more advanced disease with the development of distant metastases (P ¼ 0.036). The occurrence of metastases in TRAMP tumors was primarily observed in the paraaortic lymph nodes (LNs), lungs and liver (Gingrich et al., 1996; Kaplan-Lefko et al., 2003) , and was observed only in older mice (X31 weeks). T þ /SP À/À (4/12) mice developed distant metastases at one or more secondary sites, whereas one T þ /SP þ / þ mouse (1/10) developed metastases in lymph nodes, lung and liver (Po0.05). The expression of SPARC protein in T þ /SP þ / þ tumors decreased as a function of tumor aggressiveness (Figure 1ci ). Interestingly, comparison of SPARC expression between primary tumors of PD histology and secondary metastases in the T þ /SP þ / þ mouse showed increased expression in paraaortic LNs and lungs, but not in liver (Figure 1cii ).
SPARC affects expression of cell-cycle proteins
Despite no discernible microscopic differences between tumors developing in either genotype, PIN as well as WD and PD adeno in T þ /SP À/À mice exhibited an increase in proliferating cells as determined by Ki67 immunostaining (PIN, WD: Figures 2ai and ii, PD: data not shown). As SPARC can induce cell-cycle arrest in mid-G 1 phase in mesenchymal and epithelial cells, delaying progression to S-phase (Basu et al., 1999; Bradshaw et al., 1999; Motamed et al., 2002; Francki et al., 2003) , we evaluated whether SPARC can alter the cell cycle in TRAMP tumors. We found that in PIN the expression of cyclin A1 and D1, but not cyclin E2, was significantly higher in
and ii). The expression of p21
Cip , p27
. These differences in expression were maintained as prostate cancer progressed to adenocarcinoma (data not shown). 
The overall association between tumor histology, mouse genotype and time in each lobe was performed by applying the Cochran-Mantel-Haenszel test to the three-way cross-classification as described in Materials and methods. Within each lobe, a comparison of tumor histology as a function of genotype (
was carried out using the Kruskal-Wallis test as described in Materials and methods (*P ¼ 0.005, y P ¼ 0.059, and **P ¼ 0.036). (c) The expression of SPARC during prostate cancer progression in
normal prostates or prostates with prostate intraepithelial neoplasia (PIN), well-differentiated adenocarcinoma (WD adeno) or poorly differentiated adenocarcinoma (PD adeno) (i), as well as from an animal with prostate PD adeno and lymph node (LN), lung and metastases (ii) were subjected to western blotting. Blots were probed with antimurine SPARC. Equal protein loading was ensured by probing the membranes for a-tubulin. Relative band intensity was measured by Apha Innotech software and is shown in relation to that of the primary tumor assigned a value of one.
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To determine if SPARC exerts similar effects on human prostate cancer, we used human prostate cancer cell lines, DU145, PC3 and LNCaP (with low, absent or detectable endogenous SPARC respectively; Thomas et al., 2000; Wang et al., 2005; Wong et al., 2008) and transiently transfected them with pSPARC. Western blot analysis of cell-cycle regulatory proteins revealed that transient overexpression of pSPARC decreased expression of cyclins A and D1 concomitant with upregulation of p21 Cip and p27 kip ( Figure 2c ). Flow cytometric analysis of the cell cycle revealed cell-cycle changes at G 1 /S phases in both PC3 and DU145 cell lines (Supplementary Table 1 ).
Tumor and host SPARC both affect prostate cancer cell growth and invasion To directly assess the role of tumor SPARC in carcinoma growth and invasion, we used the three TRAMP cell lines (TRAMP-C1, TRAMP-C2 and TRAMP-C3; http://www.thegreenberglab.fhcrc.org). We evaluated their in vitro growth and invasiveness, relative to their SPARC expression. The three cell lines expressed SPARC mRNA and protein, and secreted it in conditioned media (CM; Figure 3ai ). The proliferation rates and invasiveness were inversely correlated with endogenous SPARC level. TRAMP-C1 and TRAMP-C2 had similar SPARC levels, proliferation rate ( Figure 3aii ) and matrix invasiveness (Figure 3aiii ). 
(ii) Bars represent mean ± s.e.m. of Ki67-stained nuclei counted in 6 random fields of 5 age-matched (ii) Bars represent mean±s.e.m. of densitometric analysis of the relative expression levels of cell-cycles markers, normalized to corresponding a-tubulin level. (c) The effect of SPARC on human prostate cancer cell lines was analysed on pooled populations of DU145, PC3 and LNCaP cells. Cells were grown to 60% confluence in six-well plates and were transiently transfected with 1.5 mg/well pSPARC or equivalent concentration of pcDNA3.1 in OPTIMEM for 16 h, then were allowed to recover in complete growth medium for further 48 h. Cells were then lysed in RIPA buffer, and the expression of cell-cycle proteins and their inhibitors was determined in 20 mg of cell lysates by western blotting, Protein loading was verified by a-tubulin membrane probing. Relative band intensity was measured by Apha Innotech software and it represents the change in expression of cell-cycle regulators in cells transfected with pSPARC relative to pcDNA3.1 controls.
All were modestly, though significantly, higher in TRAMP-C3. In vivo, subcutaneous (SC) implantation of TRAMP-C2 cells in SP À/À and their SP þ / þ age-matched syngeneic mice resulted in 10/10 (100%) SC tumor development compared to 6/10 (60%) in the SP þ / þ (Po0.05, w 2 -test), whereas TRAMP-C3 injection did not result in tumor formation in either genotype. Similarly, forced expression of SPARC in human prostate cancer cell lines induced significant dose-dependent inhibition of proliferation and matrix (ii) Proliferation of TRAMP cell lines was compared. Cells (5000 cells/well) were seeded in 96-well plates and proliferation compared 48 h later using Alamar blue assay and measuring the fluorescence at 590 nM. Bars represent mean ± s.e.m. of three independent experiments performed in sextuplicates (*Po0.05, Student's t-test). (iii) Invasion of extracellular matrix (ECM) proteins by TRAMP cells was examined. Transwell inserts were coated with 50 mg/ml Collagen I (Col I), Col IV, fibronectin (FN) and 10 mg/ml laminin (LM) for 2 h at 37 1C, washed with phosphate-buffered saline (PBS) and were incubated with PBS-2% bovine serum albumin (BSA) to block nonspecific binding. TRAMP cell lines (1 Â 10 5 cells/100 ml serum-free medium containing 0.4% BSA) were added to the upper chamber of the inserts, the bottom chambers contained complete growth medium (CGM) and allowed to invade the ECM-coated inserts. At the end of 5 h, the contents of upper surface of the inserts were removed by cotton swabs and invading cells at the bottom surface of the inserts were stained with DiffQuick and counted in six random high power fields/insert, using an inverted microscope equipped with DFC 320 digital camera (Leica Microsystems, Wetzlar, Germany), under Â 200 magnification. Bars represent the mean±s.e.m. of three independent experiments performed in quadruplicates (*Po0.05, Student's t-test). (b) Forced expression of SPARC in human prostate cancer cell lines PC3, DU145 and LNCaP by transient transfection with 0-2.5 mg pSPARC and pcDNA3.1 vector control resulted in concentration-dependent increase in endogenous SPARC expression as determined by western blotting (i). PC3, DU145 and LNCaP cells were transiently transfected with the indicated concentrations of pSPARC for 16 h and were allowed to recover for 24 h. Cells were then seeded in 96-well plates (5000 cells/well) and proliferation compared 48 h later using Alamar blue assay (ii). Similarly transfected cells were then seeded on matrigel-coated inserts (1 Â 10 5 cells/100 ml serum-free medium containing 0.4% BSA) and allowed to invade for 5 h. (iii) Cells on the undersurface of the filters were counted after staining with DiffQuick stain. Bars represent the mean±s.e. of three independent experiments performed in quadruplicates (*Po0.05, Student's t-test). (Figures 3bi-iii) . Conversely, silencing SPARC expression in human (DU145 and LNCaP; Figure 4a ) and the three TRAMP cell lines (Figure 4b ) resulted in significant acceleration of their proliferation (Btwofold increase) and matrix invasiveness (25-35%).
SPARC in prostate cancer
Exogenous SPARC exerted an antiproliferative effect of SPARC on DU145, PC3 and LNCaP at concentrations higher than 20 mg/ml with 40-50% inhibition at 80 mg/ml (Supplementary Figure 2A) , with no effect on TRAMP cells proliferation (data not shown). Consistent with earlier reports (Koblinski et al., 2005; Chen et al., 2007) , human prostate cancer cell lines PC3 and DU145, but not LNCaP, exhibited B1-to 2-fold increase in migration toward SPARC (1-5 mg/ml in the bottom chambers of transwells), then reached a plateau at higher concentrations (Supplementary Figure  2Bi) . TRAMP cells exhibited 25-30% increase in migration toward SPARC (5 mg/ml; Supplementary  Figure 2Bii ).
Host SPARC affects intratumoral collagen and proteolytic activity Subcutaneous implantation of TRAMP-C2 in SP À/À mice, resulted in significantly larger tumors than SP þ / þ mice at 10 weeks postimplantation (Figure 5ai ). To gain insight as to the molecular changes underlying the enhanced tumorigenicity of TRAMP-C2 cells in SP À/À mice, we evaluated ECM components previously reported to be decreased in tumors growing in SP À/À mice Puolakkainen et al., 2004; Said and Motamed, 2005) . We found that TRAMP-C2 growth in SP À/À mice was associated with significant reduction of Collagen I (Col I), but not Col IV mRNA (Figure 5aii ). Masson's trichrome stain (Figure 5aiii ) and picrosirius red staining (Figure 5aiv (ii) Proliferation assays were carried out as described above 24 h after transfection with siSPARC in DU145 and LNCaP cells. Cell proliferation was determined 48 h later using Alamar blue assay. Bars represent mean±s.e.m. of three independent experiments performed in sextuplicates (*Po0.05, Student's t-test). (iii) Migration (and matrix invasiveness of DU145 and LNCaP cells transfected with siSPARC was determined using matrigel-coated transwell inserts as described above. Cells on the undersurface of the filters were counted after staining with DiffQuick stain. Bars represent the mean ± s.e. of three independent experiments performed in quadruplicates (*Po0.05, Student's t-test). (b) Similarly, SPARC expression was efficiently knocked down in the three TRAMP cell lines after transfection with 150 nM specific siRNA oligonucleotides targeting murine SPARC (i) and lipofectamine 2000 (1:1.5), as determined by western blotting of the cell lysates 72 h after transfection. (ii) Proliferation assays were carried out using Alamar blue as described above 24 h after transfection with siSPARC in the three TRAMP cell lines. Cell proliferation was determined 48 h later using Alamar blue assay. Bars represent mean±s.e.m. of three independent experiments performed in sextuplicates (*Po0.05, Student's t-test). (iii) Migration and matrix invasiveness of TRAMP cell lines transfected with siSPARC was determined using matrigel-coated transwell inserts as described above. Bars represent the mean ± s.e. of three independent experiments performed in quadruplicates (*Po0.05, Student's t-test). (Figure 6b ).
Effect of SPARC on the cytokine tumor microenvironment in TRAMP mice As stromal cells have been shown to induce an array of proinflammatory, mitogenic and angiogenic cytokines, including interleukin-6 (IL-6) and macrophage chemotactic protein-1 (MCP-1) in prostate cancer, we observed that PIN was associated with a significant increase in MCP-1 and IL-6 levels compared to normal prostate (Figures 6ci-iii) . Increases in MCP-1, IL-6 and VEGF levels were observed in WD aden and PD adeno and were significantly higher in T þ /SP À/À tumors than in the T þ /SP þ / þ counterparts in those histologies. In addition to the increased VEGF levels, T þ /SP À/À adenocarcinomas exhibited significantly increased MVD, compared to Figure 3B) .
Discussion
This study was designed to elucidate the effects of tumor and host SPARC in primary prostate cancer initiation, growth and metastasis. Deregulation of the cell cycle is one of the most common features of all prostate cancers, specifically, the upregulation of cyclin D1 and its 
showing proteolytic activity of pro-and active matrix metalloproteinases (MMP-2 and MMP-9). Equivalent tissue samples with protein concentrations were subjected to SDS-polyacrylamide gel electrophoresis (PAGE), western blotting and probing for a-tubulin to ensure equal protein loading. (c)Determination of the levels of macrophage chemotactic protein-1 (MCP-1) (i), interleukin-6 (IL-6) (ii) and vascular endothelial growth factor (VEGF) (iii) in tissue lysates of normal prostates from nontransgenic (NT) SP þ / þ (n ¼ 3) and SP À/À (n ¼ 2), and
, and PIN (n ¼ 5 each genotype), well-differentiated (WD) adenocarcinoma (n ¼ 5 each genotype) and poorly differentiated (PD) adenocarcinoma (n ¼ 5 each genotype), from the p20 weeks and X30 cohorts of
and T þ /SP À/À mice, respectively (*Po0.05, Student's t-test; **Po0.001, one-way analysis of variance (ANOVA)).
SPARC in prostate cancer N Said et al positive correlation with prostate cancer metastasis (Comstock et al., 2007) . Conversely, upregulation of p21 Cip and/or p27 Kip inhibits the activity of most cyclin/ cyclin-dependent kinase complexes, causing growth inhibition in prostate cancer (Roy et al., 2007) . Crossing TRAMP mice with SPARC-null mice and generation of T þ /SP þ / þ and T þ /SP À/À allowed us to study the effect of SPARC on early phases of transformation and carcinogenesis. The accelerated tumorigenesis in T þ /SP À/À is consistent with earlier reports of the modulation of the steady-state as well as growth factor-driven cell-cycle progression in epithelial and mesenchymal cells by SPARC, in which steady-state levels of the G 1 phase protein cyclins D and A are decreased whereas their inhibitors p21
Cip and p27 Kip are elevated (Basu et al., 1999; Bradshaw et al., 1999; Motamed et al., 2002; Francki et al., 2003) . These findings are in accord with the reports describing the decreased SPARC expression in primary prostate tumors compared to normal prostates and secondary metastatic sites (Thomas et al., 2000; Wong et al., 2008) , and also parallel the reported differential expression of SPARC and its regulator p45-sErb3 (Chen et al., 2007) .
Consistent with our in vivo model, the antiproliferative effect of SPARC on human prostate cancer cell lines in vitro was associated with decreased levels of cyclins A and D1 with increase in p21
Cip /p27
Kip . The effect of SPARC on these cyclins may explain the antiproliferative effect of SPARC on other human cancer cells (Sato et al., 2003; Said and Motamed, 2005; Suzuki et al., 2005; Podhajcer et al., 2008) . Given that p21
Cip and transforming growth factor-b (TGF-b1) expression have been correlated with disease-free survival for patients with non-small cell lung cancer (Bennett et al., 1998) and the established positivefeedback loop between SPARC and TGF-b (Francki et al., 2003) , it is plausible that the antiproliferative effect of SPARC is mediated through the TGF-b pathway. The antiproliferative and antiinvasive effects of tumor SPARC in prostate cancer cell lines are consistent with earlier reports in MDA-231 breast cancer cell lines (Koblinski et al., 2005) inhibiting their proliferation and invasiveness when overexpressed, and paradoxically exerting a chemotactic effect in an in vitro chemotaxis assay. Together, these imply different roles of endogenous SPARC versus exogenous SPARC in cancer cells.
The interaction between cancer cells with the surrounding stroma can generate a tumor microenvironment characterized by ECM remodeling, elevated protease activity, growth factor production and angiogenesis, providing a favorable milieu for tumor survival and progression (Said et al., 2007a; Podhajcer et al., 2008) . SPARC has been shown to limit tumor growth and angiogenesis in syngeneic pancreatic, Lewis lung and ovarian cancer models in immunocompetent SP þ / þ and SP À/À mice Koukourakis et al., 2003; Puolakkainen et al., 2004; Said and Motamed, 2005; Said et al., 2007b) as well as in xenografts in immunocompromised mice (Chlenski et al., 2006) . Using murine TRAMP (Greenberg et al., 1995; Gingrich et al., 1996) cell lines to form SC tumor implants in SP þ / þ and SP À/À mice, and examining prostate tumors form T þ /SP þ / þ and T þ /SP À/À we found that host SPARC retards tumor growth, and this is associated with enhanced maturity of fibrillar collagen at the tumor periphery, decreased angiogenesis and proteolytic activity.
The antiangiogenic effect of SPARC has been attributed to the EGF-like structure of its follistatin domain (Chlenski et al., 2006) and cell-cycle arrest of endothelial and vascular smooth muscle cells at the G 1 /S phase; PDGF, VEGF and bFGF are also inhibited from binding to their cognate receptors on these cells (Basu et al., 1999; Bradshaw et al., 1999; Motamed et al., 2002; Francki et al., 2003) . The suppressive effects of SPARC on prostate cancer reported herein may, in part, be attributed to its negative effect on the constituents of the tumor microenvironment. Moreover, the enhanced proteolytic activity observed in the T þ /SP À/À prostate tumors may lead to increased tumor angiogenesis by increasing the bioavailability of angiogenic growth factors and proangiogenic inflammatory cytokines such as VEGF (and bFGF), IL-6, and MCP-1, as well as making the ECM more permissive for neovascular growth and sprouting (Chlenski et al., 2006 (Chlenski et al., , 2007 .
One of the noteworthy limitations of the TRAMP model for human prostate cancer is that bone metastasis is rare (Gingrich et al., 1996; Kaplan-Lefko et al., 2003) . We have also been unable to detect any macroscopic or microscopic bone metastases in either T þ /SP À/À or T þ /SP þ / þ mice followed for more than 70 weeks of age (data not shown). However, we have shown that SPARC is overexpressed in lymph node metastasis compared to its primary tumor. Our results have also shown that SPARC downregulates the production of VEGF, MCP-1 and IL-6 by prostate tumors. These soluble factors have been implicated in the crosstalk between prostate cancer cells and cellular components of the bone microenvironment (De et al., 2003; Bussard et al., 2008) presumably preconditioning a niche to support homing of continually shed prostate cancer cells (Buijs et al., 2007; Comstock et al., 2007; Kingsley et al., 2007; Woodward et al., 2007) . Our findings support earlier reports that SPARC can act as a chemotactic factor (Jacob et al., 1999; De et al., 2003; Chen et al., 2007) . Thus, we can postulate that stromal SPARC within the bone microenvironment may be responsible for homing of prostate cancer cells to bone.
In summary, our results demonstrate the role of SPARC in the primary prostate tumors that both tumor and host SPARC can decrease primary prostate cancer growth, and that SPARC can limit soft tissue metastasis in the TRAMP model. These effects are associated with changes in tumor cell-cycle protein levels as well as modulation of cellular and soluble components of the tumor microenvironment, likely rendering it unfavorable to prostate cancer growth and progression at the primary site.
Materials and methods
Cell lines, transfections, reagents, western blot and RNA analyses Human prostate cancer cell lines PC3, DU145 and LNCaP, and murine prostate cancer cell lines TRAMP-C1, -C2 and -C3 (C57/ BL6 background; Greenberg et al., 1995) were obtained from ATCC (Manassas, VA, USA), and maintained as recommended. Polyclonal and monoclonal antibodies to the following proteins were used: cyclins A, D1, E2, p21
Cip and p27 Kip (Santa Cruz Biotechnologies Inc., Santa Cruz, CA, USA); Ki 67 and SV40-large T (Abcam, Cambridge, MA, USA); mouse and human SPARC (R&D Systems Inc., Minneapolis, MN, USA); human osteonectin (AON-5031; Haematologic Technology, Essex, VT, USA); CD31 (BD Biosciences, San Jose, CA, USA); a-tubulin (Sigma, St Louis, MO, USA). SPARC from mouse parietal yolk sac was purchased from Sigma. Human osteonectin was from (Haematologic Technology). Col I from rat tail, mouse Col IV, mouse EHS laminin (LM), reduced growth factor matrigel and human plasma fibronectin (FN) were purchased from BD Biosciences. Unless otherwise stated, all other chemicals were purchased from Sigma or Fisher Scientific (Pittsburgh, PA, USA). Alamar blue was from Invitrogen (Carlsbad, CA, USA).
Western blot analysis was carried out as described (Said et al., 2007b) , using SuperSignal Femto Maximum Sensitivity Substrate (Pierce, Rockford, IL, USA) with the antibodies described above. Chemiluminescence was detected and quantitated with FluoroChem 8800 (Alpha Innotech Corporation, San Leandro, CA, USA). Membranes were then stripped of antibodies, and reprobed with monoclonal antibody against atubulin to ensure equal protein loading. RNA was isolated from cells and tissues and purified as described (Seraj et al., 2001) . Reverse-transcribed cDNA was amplified using specific murine oligonucleotide primers and reaction parameters described previously (Said and Motamed, 2005; Said et al., 2007b) . PC3, LNCaP and DU145 cell lines were transiently transfected with pSPARC (Said et al., 2007c) using Fugene 6 (Roche Applied Science, Indianapolis, IN, USA) according to the manufacturer's instructions. Human and murine prostate cancer cell lines were transfected with small interference RNA (siRNA) duplexes against human and murine SPARC mRNA (SMARTpool) or with scrambled mock siRNA obtained commercially (Dharmacon, Lafayette, CO, USA). siRNA transfection using LipofectAMINE 2000 (Invitrogen) was done according to the manufacturer's protocol.
Generation of TRAMP mice with germline deletion of SPARC gene C57BL/6 Â 129SvJ SPARC-null (SP À/À ) and wild-type (SP þ / þ ) mice were a kind gift of Dr Helene Sage (Hope Heart Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA) to KM. Mice were backcrossed against wild-type C57BL/6 mice for at least 20 generations before use in tumor studies. C57BL/6-Tg-824Ng/J TRAMP mice (T þ ) were obtained from Jackson Laboratories (Bar Harbor, ME, USA). TRAMP females were mated to male SP À/À mice.
males and females were then crossed to generate T þ /SP À/À and T þ /SP þ / þ animals. Genotyping was performed as described (Sage et al., 1989; Greenberg et al., 1995) . Male animals were used after the fourth progeny. The baseline gross morphology and glandular architecture of SP À/À was examined in 8-weekold mice (Sugimura et al., 1986) .
males were assigned to three cohorts and prostate lobes were isolated (Sugimura et al., 1986) . Paraaortic LN, livers and lungs were examined for visible metastases, and were processed for histopathology or were snap frozen. All animal procedures were approved by the IACUC of the University of Virginia.
In vivo tumor xenografts, histology and immunohistochemistry Subcutaneous tumors were generated by injecting TRAMP-C2 and TRAMP-C3 cells (5 Â 10 6 cells/0.5 ml phosphate-buffered saline (PBS)) subcutaneously into the flank of 8-week-old mice. Animals were monitored twice weekly for tumor development, and tumors were measured as described (Said and Motamed, 2005) . Formalin-fixed, paraffin-embedded tissues were deparaffinized and stained with hematoxylin and eosin (H&E), Masson's trichrome and Picrosirius red (Said and Motamed, 2005) . For immunostaining, deparaffinized sections were incubated with antibodies to Ki-67 and CD 31. Specificity of peroxidase immunostaining was ensured by using an isotype immunoglobulin G control.
Invasion and proliferation assays
Invasion assays were performed as previously described (Said and Motamed, 2005) . The chemotactic effect of SPARC on human and murine prostate cancer cell line was determined by allowing cells in the upper chambers to migrate toward the indicated concentrations of SPARC as earlier described (Koblinski et al., 2005; Chen et al., 2007) . Cell proliferation of human prostate cancer cell lines was determined after transient transfection with pSPARC, for 24 h, as described in figure legends. Alternatively, the effect of exogenous SPARC on cell proliferation was determined as earlier described (Motamed et al., 2002; Francki et al., 2003; Said and Motamed, 2005) .
Gelatin zymography and VEGF, IL-6 and MCP-1 ELISA Conditioned media from TRAMP cells were concentrated 10 Â with 10-kD Centricon tubes (Millipore, Bedford, MA, USA). Prostate tumors were homogenized in ice-cold PBS with 0.1% Triton X-100. Gelatinolytic activity was detected as earlier described (Said and Motamed, 2005) . Mouse IL-6, MCP-1 and VEGF were determined in prostate tissue lysates by enzymelinked immunosorbent assay (ELISA) kits (RayBiotech, Norcross, GA, USA) as per manufacturer's instructions.
Statistical analysis
An overall assessment of the association between tumor histology, mouse genotype, adjusted for time in each lobe was performed by applying the Cochran-Mantel-Haenszel test to the three-way cross-classification of time (p20 weeks, 21-30 weeks, X31 weeks) by histology by T þ /SP À/À and T þ /SP þ / þ group. A more detailed assessment was made by applying the w 2 -test was to each 5 Â 2 table cross-classifying prostate histology between T þ /SP À/À and T þ /SP þ / þ within each time category (p20 weeks, 21-30 weeks, X31 weeks) and within each lobe. The Kruskal-Wallis test was used to compare the tumor burden score between T þ /SP À/À and T þ /SP þ / þ groups within each time group. Tumor burden was defined as the sum of the following scores when the specific finding is present/absent in each mouse: normal ¼ 0; PIN ¼ 1; WD adeno ¼ 2; PD adeno ¼ 3; SCC and PLL tumors ¼ 4 (Kaplan- Lefko et al., 2003) ; the presence of metastases in resected LNs, lungs and livers ¼ 5. All other comparisons between T þ /SP À/À and T þ /SP þ / þ groups were performed with twosample t-test. The changes of MCP-1, IL-6 and VEGF levels as a function of tumor progression in either T þ /SP À/À and T þ /SP þ / þ tumors were analysed by one-way analysis of variance (ANOVA). Analyses were carried out in SAS 9.1 (Statistical Analysis System; SAS Institute, Cary, NC, USA) and Microsoft Excel. Comparisons were considered significant at Po0.05.
